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Abstract
Background and objective: Lack of regular blood transfusions in patients with intermediate thalassemia leads to a higher probability of pulmonary arterial hypertension 
(PAH) in comparison with other patients. PAH remain a concern in thalassemia patients. The aim of this study was to find the prevalence of PAH in patients with 
thalassemia.
Methods: In this Cross-Sectional study, sixty three matched patients were consecutively admitted to hospital and divided to two groups (29 intermediate and 34 major 
thalassemia patients). Echocardiography, Complete Blood Count (CBC) and ferritin analysis were done for both groups. The mean pulmonary artery systolic pressure 
(PASP) values ≥25 mmHg defined as PAH. Patients with TI were treated by Hydroxyurea and didn’t need regular monthly blood transfusions for maintaining their 
hemoglobin levels above 9.5. Data collected for each group patients and then analyzed by Statistical methods in SPSS.19. 
Results: The prevalence of PAH in patients with TI with 12(41.4%) was significantly 2.8 time higher than patients with TM with 5(14.7%).(p=0.018) Variables such 
as sex, marital status, age, nucleated red blood cells(NRBC),heart failure, ECG change rate were similar between two groups.
Conclussion: PAH in patients with thalassemia intermediate which treated with Hydroxyurea were significantly more than patients with thalassemia major which 
receiving regular blood transfusions. Therefore, it was recommended that before appearance the symptoms of pulmonary hypertension in the patients with thalassemia 
intermediate, especially males, regular blood transfusions to be started in these groups.
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Introduction
Pulmonary Hypertension (PHT) is a clinical entity which is not 
uncommon in thalasemic patients. Thalassemia make a heterogeneous 
group of inherited anemia due to mutations occurred in the genes 
formulating hemoglobin. Weaker gene mutations are more frequent, 
while severe gene mutations are rare [1]. There are a lot of patients 
who, clinically, have more severe symptoms than minor thalassemia, 
but the severity of their anemia is not SAME AS major which is called 
thalassemia major [2]. Today, most experts agree that only a group of 
thalassemic patients with hemoglobin level between 6 - 10 g/dl who 
have reached puberty can be included in the category of thalassemia 
intermediate. However, there are some thalassemia intermediate cases 
with hemoglobin level above 10 g/dl who remain undiagnosed until 
puberty, but these cases are rare [2].
Talassemia has numerous complications such as pulmonary 
hypertension which is caused by pulmonary Hemocidrosis, special 
chest shape, extra medullary hematopoiesis and rise of coagulability 
status in patients with intermediate [3-6].
Regular blood transfusions in the thalassemia can prevent 
pulmonary hypertension. It appears that the probability of pulmonary 
hypertension in thalassemia intermedia is higher than thalassemia 
major [7]. The aim of this study was to investigate prevalence and risk 
factors of pulmonary hypertension (PH) in patients with thalassemia 
under treatment with Hydroxyurea and its related factors.
Methods
Type of study
This cross-sectional study was conducted on 63 thalassemia 
patients who had referred to the clinic for treating Thalassemia. From 
all thalassemia patients, 29 patients with thalassemia intermediate (TI) 
were chosen as group I and 34 patients with thalassemia major (TM) 
as group II.
In this study, those were chosen as the thalassemia intermediate 
patients were treated by Hydroxyurea and didn’t need regular monthly 
blood transfusions for maintaining their hemoglobin levels above 9.5. 
The Mean pulmonary pressure above 25 mmHg was considered as the 
pulmonary hypertension. In patients of both groups variables such as 
age, sex and NRBC were matched and the ECG and Echocardiography 
were done for all patients in two groups. Data collected by a checklist 
included some variables such as age, sex, marital status, blood transfusions’ 
frequency, the mean of ferritin level over the last year, having pulmonary 
hypertension, heart failure, Splenectomy and ECG changes. 
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Statistical analysis
The data were analyzed using SPSS version 19 through descriptive 
and analytical statistical methods. Mean ± SD and frequency and 
percent were used to describe data. Independent t-test and chi-square 
used for compare data between groups. The level of significance was 
considered P<0.05.
Ethical Considerations 
Verbal consent was obtained from patients. The design of study 
was approved by ethical committee of the University and registered 
in IRCT.
Results
In this study, 63 patients participated which from them 29(46%) 
have TI and 34(54%) have TM. Of the TI patients, 11 (37.9%) had ECG 
changes. Most of patients in TI group (65.5%) had ferritin below 1000. 
Of TI patients 12(41.4%) and from TM patients 5(14.7%) have PH 
and the prevalence of PH in patients with thalassemia intermediate is 
significantly 2.8 time higher than TM patients (P=0.018) (Table 1).
It was found that in TI group, of 12 patients with pulmonary 
hypertension 10 cases (83.3%) were male and 2 (16.7%) were female with 
ratio 10:2. The average level of hemoglobin in the group with pulmonary 
hypertension and the group without pulmonary hypertension was 
9.1 ± 1.1, and 9.4 ± 0.8, respectively, but not statistically significant. 
The mean NRBC in the group with pulmonary hypertension was 155 
± 71.5, and in the group without pulmonary hypertension was 89.2 
± 38.9, which showed no statistically significant difference between 
two groups. Table 2 of the 12 thalassemia intermediate patients who 
had pulmonary hypertension, ten (83.3%) had ECG changes and of 5 
thalassemia major patients who had pulmonary hypertension, all had 
ECG changes. However, there was statistically significant difference 
between the rate of pulmonary hypertension between two groups. 
Most of the patients with thalassemia intermedia had ferritin below 
1000 with 65.5% and Most of patients with major thalassemia have 
ferritin in range 1000-4000 with 73.5%.
Discussion
The phenotype of thalassemia intermediate stands between 
thalassemia minor and thalassemia major. The presence of a range of 
clinical symptoms for thalassemia intermediate shows the specificity 
of each patient in terms of the treatment that s/he should receive. 
Despite availability of several therapeutic approaches, lack of a clear 
and practical guide can lead to serious doubts over treatment [8].
The severity of clinical outcome largely depends on the initial 
molecular defects. Deposition of α chains in erythroid precursors in 
the bone marrow can cause damage to cell membranes and premature 
cell death and ineffective hematopoiesis. Highly ineffective primary 
hematopoiesis is determinant of anemia. In addition to complications 
and common symptoms of thalassemia, a series of specific complications 
can be seen in thalassemia intermediate due to lack of regular blood 
transfusions and iron chelation, which is rare in thalassemia major, 
like gallstones, extra medullary hematopoiesis, kidney stones, leg ulcers 
and increased thrombophilia and pulmonary hypertension and right 
heart’s failure [8]. 
It seems that the right heart’s failure in this group of patients 
emanates from pulmonary hypertension. The mechanism of pulmonary 
hypertension in thalassemia intermediate has not been obviously 
recognized yet. Inasmuch as anemia and iron overload are very 
uncommon in the patients with thalassemia major who receive sufficient 
blood transfusions and iron chelation, it appears that these two actions 
are the basis for pathophysiology in pulmonary hypertension [2-3,8]. 
Hereupon, taking regular blood transfusions and iron chelation in 
patients with thalassemia intermediate in early stages where pulmonary 
hypertension symptoms occur, seems necessary. In this study, we made 
an effort to draw a comparison between patients with thalassemia major 
and patients with thalassemia intermediate in terms of pulmonary 
hypertension and determine the factors associated with pulmonary 
hypertension in patients with thalassemia intermediate, with the 
purpose of avoiding pulmonary hypertension by starting early blood 
transfusions. Currently, treatment with Hydroxyurea is considered as 
the first rational choice to treat thalassemia intermediate, while blood 
transfusion and iron chelation are performed only in particular cases 
determined by the patient’s condition. Of the 63 patients studied, 17 
patients (27%) had pulmonary hypertension that 12 patients (41.4%) 
out of this number belonged to thalassemia intermediate group and 
rest of them, i.e., five patients (14.4%), belonged to thalassemia major 
group. It was also shown that the rate of PAH in patients with TI was 
significantly higher than patients with thalassemia major (P=0.018). 
In similar studies undertaken over patients with TI, the pulmonary 
hypertension has been assessed in range 4.3%-100% and 60% whose 
outcomes show higher rates of pulmonary hypertension prevalence in 
TI patients [9-14].
The incidence rate of pulmonary hypertension in patients with 
thalassemia major who received regular blood transfusions and iron 
chelation was much less and confirmed the findings of previous studies 
[4,8,10-13].
Pulmonary hypertension in the male patients with thalassemia 
intermediate was significantly greater than female patients (P=0.047), 
that suggests early start of regular blood transfusions and examination 
of pulmonary hypertension in male patients. Although, there wasn’t 
                         Group 
Variables
Intermedia (n=29) Major (n=34) p-value
Sex[n(%)]  
Male 18(62.1) 21(61.8) 0.6
Female 11(37.9) 13(39.2)
Marital status
Married 14(48.3) 17(50) 0.5
Single 15(51.7) 17(50)
PAH 12(70.6) 5(14.7) 0.018
Age mean ± SD 17.7 ± 5.5 19.3 ± 7.2 0.3
Hb mean ± SD 9.3 ± 0.9 8.3 ± 1.2 0.001
NRBC mean ± SD 116.3 ± 37.1 84.4 ± 43.4 0.58
ECG change rate 11(37.9) 8(23.5) 0.12
Heart failure rate 2(6.9) 3(8.8) 0.6
Ferritin Levels  <1000 19(65.5) 3(8.8) 0.001
1000-4000 9(31) 25(73.5)
>4000 1(3.4) 6(17.6)
Table 1. Comparison between the two studied groups as regard different variables.
                         Group 
Variables
PAH+ (N=17) PAH-(N=46) p-value
Sex[n(%)]  
Male 10 (83.3) 29 (63) 0.047
Female 7 (16.7) 22 (37)
Hb mean ± SD 9.1 ± 1.1 9.4 ± 0.8 0.24
NRBC mean ± SD 155 ± 71.5 89.2 ± 38.9 0.46
ECG change rate 15 (88.2) 2 (4.3) 0.001
Table 2. Comparison between PAH and non PAH as regard different variables.
Fathi A (2016) Prevalence of pulmonary artery hypertension (pah) in patients with thalassemia 
 Volume 1(4): 95-97Pediatr Dimensions, 2016         doi: 10.15761/PD.1000121
any significant relationship between the mean of hemoglobin/NRBC’s 
level and developing pulmonary hypertension in patients with 
thalassemia intermediate. The mean of hemoglobin in the individuals 
with thalassemia intermediate who had pulmonary hypertension 
was lower. In this case, it can be recommended that early blood 
transfusion and Deferoxamine injection to be performed when 
the hemoglobin level is low and NRBC level is high. There was no 
significant relationship between pulmonary hypertension in patients 
with thalassemia intermediate and the mean age of them. This result 
might indicate that age cannot be good criteria for predicting when 
pulmonary hypertension may occur and deciding when to start iron 
chelation, as evidence, pulmonary hypertension has been observed 
in the individuals with lower ages. There was significant relationship 
between ECG changes and pulmonary hypertension in patients with 
thalassemia intermediate (P=0.001), indicating that ECG changes 
beside changes induced by pulmonary hypertension can be helpful 
in predicting pulmonary hypertension. There was no significant 
relationship between the mean of ferritin level and pulmonary 
hypertension in patients with thalassemia intermediate (P=0.233). 
Thus we could say that the ferritin level cannot be good criteria to 
predict the incidence of pulmonary hypertension in patients with TI.
Conclusion
Pulmonary hypertension in patients with thalassemia intermediate 
who are treated with Hydroxyurea instead of regular blood transfusions 
and iron chelation therapy is significantly higher than in patients 
with thalassemia major. Therefore, it is recommended that patients 
with thalassemia intermediate to be regularly examined in terms 
of the incidence of pulmonary hypertension through performing 
echocardiography and to begin regular blood transfusions and iron 
chelation as soon as the symptoms of pulmonary hypertension appear, 
especially in males and in patients with low hemoglobin and high 
NRBC. 
Furthermore, because of the increasing number of platelets 
in patients with thalassemia intermediate and its association with 
pulmonary hypertension, it is suggested that future studies to be 
conducted in larger groups and the number of platelet to be counted 
and its association with pulmonary hypertension to be investigated.
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